Psychedelic Medicine – what does the future hold?

Prof David Castle

writer

Prof David Castle

Psychiatrist; Inaugural Scientific Director, Centre for Complex Interventions (CCI) at the Centre for Addictions and Mental Health (CAMH), Toronto, Canada; Professor, Department of Psychiatry, The University of Toronto Honorary Affiliation - Professor of Psychiatry at St Vincent’s Health and The University of Melbourne

Claim CPD for this activity

Educational Activities (EA)

0 hours

These are activities that expand general practice knowledge, skills and attitudes, related to your scope of practice.

Reviewing Performance (RP)

0 hours

These are activities that require reflection on feedback about your work.

Measuring Outcomes (MO)

0 hours

These are activities that use your work data to ensure quality results.

EA
0 minutes

These are activities that expand general practice knowledge, skills and attitudes, related to your scope of practice.

RP
0 minutes

These are activities that require reflection on feedback about your work.

MO
0 minutes

These are activities that use your work data to ensure quality results.

Prof David Castle

Professor David Castle, Chair Psychiatry St Vincent’s Hospital and University of Melbourne and Board Director Mind Medicine Australia, answers some of the big questions about the re-emerging field of psychedelic-assisted psychotherapy in this Q&A.

PASSWORD RESET

Forgot your password or password not working? Please enter your email address. You will receive an email with the link to set a new password.

Bonomo Y, Norman A, Biondo S, Bruno R, Daglish M, Dawe S, et al. The Australian Drug Harms Ranking Study. J Psychopharmacol. 2019 Jul; 33(7): 759-68. DOI: 10.1177/0269881119841569

Goldberg SB, Pace BT, Nicholas CR, Raison CL, Hutson PR. The experimental effects of psilocybin on symptoms of anxiety and depression: a meta-analysis. Psychiatry Res 2020 Feb; 284: 112749. DOI: 10.1016/j.psychres.2020.112749

Meikle SE, Liknaitzky P, Rossell SL, Ross M, Strauss N, Thomas N, et al. Psilocybin-assisted therapy for depression: how do we advance the field? Aust N Z J Psychiatry. 2020 Mar; 54(3): 225-31. DOI: 10.1177/0004867419888575

Mithoefer MC, Feduccia AA, Jerome L, Mithoefer A, Wagner M, Walsh Z, et al. MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomised controlled trials. Psychopharmacology (Berl). 2019 Sep: 236(9): 2735-45. DOI: 10.1007/s00213-019-05249-5

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Dr Alexander Sweetman

Dr Alexander Sweetman

Insomnia – Drug & Non-Drug Management

Dr Tracy Leong

Dr Tracy Leong

Lung Cancer Screening Has Started – What GPs Need to Know

Dr Andrew Leech

Dr Andrew Leech

Managing Paediatric Anxiety in General Practice

Prof Rodney Baber AM

Prof Rodney Baber AM

Menopausal Hot Flushes Management

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Share this

Share this

Prof David Castle

writer

Prof David Castle

Psychiatrist; Inaugural Scientific Director, Centre for Complex Interventions (CCI) at the Centre for Addictions and Mental Health (CAMH), Toronto, Canada; Professor, Department of Psychiatry, The University of Toronto Honorary Affiliation - Professor of Psychiatry at St Vincent’s Health and The University of Melbourne

Test your knowledge

Recent articles

Latest GP poll

When do you plan to retire or leave general practice?

Within the next 12 months

0%

Within the next 3 years

0%

Within the next 5 years

0%

Within the next 10 years

0%

More than 10 years

0%

Recent podcasts

Listen to expert interviews.
Click to open in a new tab

Find your area of interest

Once you confirm you’ve read this article you can complete a Patient Case Review to earn 0.5 hours CPD in the Reviewing Performance (RP) category.

Select ‘Confirm & learn‘ when you have read this article in its entirety and you will be taken to begin your Patient Case Review.

Menopause and MHT

Multiple sclerosis vs antibody disease

Using SGLT2 to reduce cardiovascular death in T2D

Peripheral arterial disease